Skip to main content

Advertisement

Log in

Analysis of Clinical Outcomes of Pseudomyxoma Peritonei from Appendicular Origin Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Retrospective Study from INDEPSO

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

To evaluate the clinical outcomes of patients of pseudomyxoma peritonei of appendiceal origin undergoing cytoreductive surgery and HIPEC. Data collected from members, an independent collaborative group of Indian surgeons specializing in the management of peritoneal surface malignancy (INDEPSO), was analyzed retrospectively. Clinicopathological and perioperative outcomes of patients treated for pseudomyxoma peritonei (PMP) of appendicular origin were evaluated. Ninety-one patients were diagnosed with pseudomyxoma peritonei of appendicular origin between March 2013 and December 2017. The median age was 53 years and 60% were females. The median PCI was 27 [range 3–39] and a CC-0/1 resection was achieved in 83.5% patients. The most common histological grade was low-grade PMP, seen in 71.4% cases. The overall rate of grades 3–4 morbidity was 33% (30/91) and the 90-day mortality rate reported was 6.5%. Pulmonary complications and systemic sepsis emerged as the most significant factors affecting morbidity, mortality, and failure to rescue. At a median follow-up of 24 months, the median OS was not reached and the median PFS was 53 months. On univariate and multivariate analysis, high-grade histology, prior chemotherapy, debulking surgery alone without HIPEC, and high PCI > 10 were predictors of poor progression-free survival. The survival and morbidity results of pseudomyxoma peritonei from appendicular origin following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are encouraging. With further awareness and understanding of the disease, and improvement in surgical expertise and learning curve, there is scope for further reduction in morbidity and better improvement in survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bevan KE, Mohamed F, Moran BJ (2010) Pseudomyxoma peritonei. World J Gastrointest Oncol 2(1):44–50

    Article  PubMed  PubMed Central  Google Scholar 

  2. Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12(3):585–603

    Article  PubMed  Google Scholar 

  3. Esquivel J, Sugarbaker PH (2000) Clinical presentation of the Pseudomyxoma peritonei syndrome. Br J Surg 87(10):1414–1418

    Article  CAS  PubMed  Google Scholar 

  4. Agrawal AK, Bobiński P, Grzebieniak Z, Rudnicki J, Marek G, Kobielak P et al (2014) Pseudomyxoma peritonei originating from urachus-case report and review of the literature. Curr Oncol Tor Ont 21(1):e155–e165

    Article  CAS  Google Scholar 

  5. Sugarbaker PH (1994) Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 219(2):109–111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH (2003) Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 22(4):465–472

    Article  PubMed  Google Scholar 

  7. Nitecki SS, Wolff BG, Schlinkert R, Sarr MG (1994) The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 219(1):51–57

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO et al (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219(2):112–119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG (2005) Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241(2):300–308

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sugarbaker PH, Chang D (1999) Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6(8):727–731

    Article  CAS  PubMed  Google Scholar 

  11. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 98(4):277–282

    Article  PubMed  Google Scholar 

  12. Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7(2):139–151

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IHJT, Ceelen WP, Pelz JO, Piso P, González-Moreno S, van der Speeten K, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 30(20):2449–2456

    Article  Google Scholar 

  14. Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 42(7):1035–1041

    CAS  Google Scholar 

  15. Glehen O, Mohamed F, Sugarbaker PH (2004) Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 240(2):278–285

    Article  PubMed  PubMed Central  Google Scholar 

  16. Benhaim L, Honoré C, Goéré D, Delhorme J-B, Elias D (2016) Huge pseudomyxoma peritonei: surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 42(4):552–557

    CAS  Google Scholar 

  17. Sugarbaker PH (2013) Cytoreductive surgery and perioperative chemotherapy: textbook and video atlas. Cine-Med Publishing, Woodbury

    Google Scholar 

  18. Chua TC, Liauw W, Zhao J, Morris DL (2011) Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Ann Surg 253(4):769–773

    Article  PubMed  Google Scholar 

  19. Austin F, Mavanur A, Sathaiah M, Steel J, Lenzner D, Ramalingam L et al (2012 May) Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol 19(5):1386–1393

    Article  PubMed  PubMed Central  Google Scholar 

  20. Newton AD, Bartlett EK, Karakousis GC (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol 7(1):99–111

    PubMed  PubMed Central  Google Scholar 

  21. Kuijpers AMJ, Mirck B, Aalbers AGJ, Nienhuijs SW, de Hingh IHJT, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JHW, te Velde EA, Verwaal VJ (2013) Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20(13):4224–4230

    Article  PubMed  PubMed Central  Google Scholar 

  22. Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B et al (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 36(5):456–462

    CAS  Google Scholar 

  23. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard A-C, Bakrin N, Cotte E, Gilly FN, Glehen O (2016) What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol 113(7):796–803

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Snita Sinukumar.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sinukumar, S., Mehta, S., AS, R. et al. Analysis of Clinical Outcomes of Pseudomyxoma Peritonei from Appendicular Origin Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Retrospective Study from INDEPSO. Indian J Surg Oncol 10 (Suppl 1), 65–70 (2019). https://doi.org/10.1007/s13193-018-00870-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-018-00870-w

Keywords

Navigation